PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity

SBKB [doi:10.1038/sbkb.2012.153]
Featured Article - August 2013
Short description: Crystal structures of 5-HT receptors bound to antimigraine drugs offer insights into ligand specificity and signaling bias.

Differences in the expanded ligand binding pocket of 5-HT1B (light blue) and 5-HT2B (green) result in conformational differences in the bound ERG (cyan and magenta, respectively). Figure courtesy of Daniel Wacker.

The neurotransmitter serotonin (5-hydroxytryptamine (5-HT)) signals through the 5-HT receptors, a family of G protein-coupled receptors (GPCRs). In addition to signaling via canonical G protein pathways, GPCRs can signal via noncanonical pathways, frequently mediated via β-arrestin. These receptors are the targets for many drugs, including antimigraine medications, antipsychotics and antidepressants, but the use of many of these drugs is complicated by side effects caused by off-target interactions with 5-HT receptor subtypes and related biogenic amine receptors. Some drugs are also able to elicit biased signaling, preferentially activating canonical or noncanonical pathways (as opposed to activating both pathways equally).

To gain a better understanding of how serotonergic drugs are recognized by 5-HT receptors, Xu, Roth, Stevens and colleagues (PSI GPCR Network) determined the structures of the antimigraine drug ergotamine (ERG) bound to its primary target, the 5-HT1B receptor (PDB 4IAR), and to the 5-HT2B receptor (PDB 4IB4). They also obtained the structure of 5-HT1B in complex with dihydroergotamine (PDB 4IAQ).

The receptors are comprised of seven transmembrane (7TM) α-helices. The ligand-binding cavity in each receptor, formed by residues in helices III, V, VI and VII, is capped by the second extracellular loop (ECL2). The ergoline ring of ERG sits deep within the 7TM core in 5-HT1B and 5-HT2B, forming similar key interactions in a conserved orthosteric binding pocket in both receptors. 5-HT1B has a much broader extended binding pocket than that of 5-HT2B, due to sequence differences and an outward shift at the extracellular end of helix V. As a result, the phenyl group of the ERG cyclic tripeptide makes different interactions with and adopts distinct conformations within each of the receptors. Mutational and docking analyses reveal that interactions with the ergoline moiety of ERG and related compounds appear to be the driving force for binding. Indeed, these results explain how the hallucinogen lysergic acid diethylamide (LSD), another ergoline, can interact promiscuously with 5-HT receptors. In contrast, triptans, antimigraine drugs that are 5-HT analogs, interact weakly with 5-HT2B because their specific shapes do not fit in the receptor's relatively small extended binding pocket.

The authors also show that LSD, ERG and other ergolines display biased signaling for β-arrestin at 5-HT2B, but are essentially unbiased at 5-HT1B. Examination of the ERG-bound crystal structures reveals that the P-I-F motif — Pro, Ile, and Phe residues found at the base of the ligand binding pocket— is in an active-like conformation in the 5-HT1B structure, but in an intermediate active one in the 5-HT2B structure. Investigation of the structural rearrangements induced on the cytoplasmic side of the receptors indicates that the 5-HT1B structure has features of an agonist-induced, activated receptor, with a shift in helix VI associated with G protein-coupled signaling. On the other hand, the 5-HT2B structure shows conformational changes in helix VII associated with β-arrestin signaling and only minor changes to helix VI, characteristics of both active and inactive states.

These findings provide a framework for understanding ligand specificity within GPCR subtypes and uncover the structural basis for signaling bias, and shall contribute to the rational development of drugs for this important receptor family.

Michelle Montoya

References

  1. C. Wang et al. Structural basis for molecular recognition at serotonin receptors.
    Science. 340, 610-614 (2013). doi:10.1126/science.1232807

  2. D. Wacker et al. Structural features for functional selectivity at serotonin receptors.
    Science. 340, 615-619 (2013). doi:10.1126/science.1232808

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health